Soleno Therapeutics (SLNO) Total Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Total Liabilities data on file, last reported at $112.6 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $112.6 million, up 31.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $112.6 million (up 31.17% YoY), and the FY2025 annual result was $113.7 million, up 32.44% from the prior year.
• Total Liabilities retreated to $112.6 million in Q1 2026 per SLNO's latest filing, from $113.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $113.7 million in Q4 2025 and troughed at $16.1 million in Q1 2022.
• A 5-year average of $49.4 million and a median of $25.5 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities decreased 24.97% in 2022, then soared 294.31% in 2025.
• A 5-year view of Total Liabilities shows it stood at $16.1 million in 2022, then surged by 43.56% to $23.2 million in 2023, then surged by 270.34% to $85.9 million in 2024, then jumped by 32.44% to $113.7 million in 2025, then retreated by 0.99% to $112.6 million in 2026.
• Business Quant data shows SLNO's Total Liabilities at $112.6 million in Q1 2026, $113.7 million in Q4 2025, and $105.1 million in Q3 2025.